We talk to Sera, our Medicines Sourcing Manager about why drug delays happen...

Why can it take us three to four weeks to deliver a medicine, and what can customers do to speed things up?

Why every little package is a big deal

Introducing a breakthrough known as 'CT1812'

How effective is alectinib (Alecensa)? The latest news and updates

 We live in an age where you can hop online to order a new brand of lipstick if it hasn’t been released yet in your country. 

Our review of the SOCAP social impact event in San Francisco.

An insight into the team, and how we constantly review our progress at TheSocialMedwork

Suggestions from cancer survivors and their children

Online counsellor Nicole Hind shares how to help our brains and bodies deal with a diagnosis.

An easy-to-understand infographic displaying the results from the clinical trial

A chat with our very first angel investor about patients, doctors and injecting innovation into the healthcare sector

Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.

For US patients and patients worldwide with ALS.

Amsterdam leads European cities as top tech destination and why it’s only natural that it is home to TheSocialMedwork.

As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.

Making an animated video for a startup on a limited budget

What makes a startup succeed?

With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.

What did we get up to, and what's next?

Get the latest news on MS research, the FDA approval of Ocrevus (ocrelizumab) for both relapsing and progressive forms of MS, insights and resources.

PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.

What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?

For the first time in 22 years, the US Food and Drug Administration (FDA) has approved a drug to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease; a motor neuron disease characterised by muscular atrophy and weakness.

Top 5 medical breakthroughs from the past, present and future

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment

Mirjam Bink’s story about her father and his attempt to access a new treatment for multiple system atrophy.

Last Thursday morning introduced us to spring, and what an entrance it made. The sun was shining, commuters passed each other with smiles, and the faint hum of summer could be heard for miles. 

The PBS, Australia’s national program responsible for providing subsidised prescriptions, has announced the addition of several new medicines

Australia’s personal importation scheme is a well-regulated system that has been around since the 1980s.